Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia

Graham S. Erwin, Paul R. Crisostomo, Yue Wang, Meijing Wang, Troy A. Markel, Mike Guzman, Ian C. Sando, Rahul Sharma, Daniel R. Meldrum

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen is implicated in the cardioprotection found in females. It remains unknown whether 17β-estradiol (E2) affects MSC paracrine function and whether E2-treated MSCs may better protect injured cardiac tissue. We hypothesize that E2-exposed MSCs infused into hearts prior to ischemia may demonstrate increased vascular endothelial growth factor (VEGF) production and greater protection of myocardial function compared to untreated MSCs. Materials and methods: Untreated and E2-treated MSCs were isolated, cultured, and plated and supernatants were harvested for VEGF assay (enzyme-linked immunosorbent assay). Adult male Sprague-Dawley rat hearts (n = 13) were isolated and perfused via Langendorff model and subjected to 15 min equilibration, 25 min warm global ischemia, and 40 min reperfusion. Hearts were randomly assigned to perfusate vehicle, untreated male MSC, or E2-treated male MSC. Transcoronary delivery of 1 million MSCs was performed immediately prior to ischemia in experimental hearts. Results: E2-treated MSCs provoked significantly more VEGF production than untreated MSCs (933.2 ± 64.9 versus 595.8 ± 10.7 pg/mL). Postischemic recovery of left ventricular developed pressure was significantly greater in hearts infused with E2-treated MSCs (66.9 ± 3.3%) than untreated MSCs (48.7 ± 3.7%) and vehicle (28.9 ± 4.6%) at end reperfusion. There was also greater recovery of the end diastolic pressure with E2-treated MSCs than untreated MSCs and vehicle. Conclusions: Preischemic infusion of MSCs protects myocardial function and viability. E2-treated MSCs may enhance this paracrine protection, which suggests that ex vivo modification of MSCs may improve therapeutic outcome.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalJournal of Surgical Research
Volume152
Issue number2
DOIs
StatePublished - Apr 2009

Fingerprint

Mesenchymal Stromal Cells
Estradiol
Ischemia
Vascular Endothelial Growth Factor A
Reperfusion
Warm Ischemia
Ventricular Pressure
Cell- and Tissue-Based Therapy
Sprague Dawley Rats
Estrogens
Stem Cells
Enzyme-Linked Immunosorbent Assay
Blood Pressure
Therapeutics

Keywords

  • cardioprotection
  • estrogen
  • paracrine
  • sex hormones
  • VEGF

ASJC Scopus subject areas

  • Surgery

Cite this

Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia. / Erwin, Graham S.; Crisostomo, Paul R.; Wang, Yue; Wang, Meijing; Markel, Troy A.; Guzman, Mike; Sando, Ian C.; Sharma, Rahul; Meldrum, Daniel R.

In: Journal of Surgical Research, Vol. 152, No. 2, 04.2009, p. 319-324.

Research output: Contribution to journalArticle

Erwin, GS, Crisostomo, PR, Wang, Y, Wang, M, Markel, TA, Guzman, M, Sando, IC, Sharma, R & Meldrum, DR 2009, 'Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia', Journal of Surgical Research, vol. 152, no. 2, pp. 319-324. https://doi.org/10.1016/j.jss.2008.02.006
Erwin, Graham S. ; Crisostomo, Paul R. ; Wang, Yue ; Wang, Meijing ; Markel, Troy A. ; Guzman, Mike ; Sando, Ian C. ; Sharma, Rahul ; Meldrum, Daniel R. / Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia. In: Journal of Surgical Research. 2009 ; Vol. 152, No. 2. pp. 319-324.
@article{32fb46d9a4ad463faa93a0994b04c032,
title = "Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia",
abstract = "Background: Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen is implicated in the cardioprotection found in females. It remains unknown whether 17β-estradiol (E2) affects MSC paracrine function and whether E2-treated MSCs may better protect injured cardiac tissue. We hypothesize that E2-exposed MSCs infused into hearts prior to ischemia may demonstrate increased vascular endothelial growth factor (VEGF) production and greater protection of myocardial function compared to untreated MSCs. Materials and methods: Untreated and E2-treated MSCs were isolated, cultured, and plated and supernatants were harvested for VEGF assay (enzyme-linked immunosorbent assay). Adult male Sprague-Dawley rat hearts (n = 13) were isolated and perfused via Langendorff model and subjected to 15 min equilibration, 25 min warm global ischemia, and 40 min reperfusion. Hearts were randomly assigned to perfusate vehicle, untreated male MSC, or E2-treated male MSC. Transcoronary delivery of 1 million MSCs was performed immediately prior to ischemia in experimental hearts. Results: E2-treated MSCs provoked significantly more VEGF production than untreated MSCs (933.2 ± 64.9 versus 595.8 ± 10.7 pg/mL). Postischemic recovery of left ventricular developed pressure was significantly greater in hearts infused with E2-treated MSCs (66.9 ± 3.3{\%}) than untreated MSCs (48.7 ± 3.7{\%}) and vehicle (28.9 ± 4.6{\%}) at end reperfusion. There was also greater recovery of the end diastolic pressure with E2-treated MSCs than untreated MSCs and vehicle. Conclusions: Preischemic infusion of MSCs protects myocardial function and viability. E2-treated MSCs may enhance this paracrine protection, which suggests that ex vivo modification of MSCs may improve therapeutic outcome.",
keywords = "cardioprotection, estrogen, paracrine, sex hormones, VEGF",
author = "Erwin, {Graham S.} and Crisostomo, {Paul R.} and Yue Wang and Meijing Wang and Markel, {Troy A.} and Mike Guzman and Sando, {Ian C.} and Rahul Sharma and Meldrum, {Daniel R.}",
year = "2009",
month = "4",
doi = "10.1016/j.jss.2008.02.006",
language = "English",
volume = "152",
pages = "319--324",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Estradiol-Treated Mesenchymal Stem Cells Improve Myocardial Recovery After Ischemia

AU - Erwin, Graham S.

AU - Crisostomo, Paul R.

AU - Wang, Yue

AU - Wang, Meijing

AU - Markel, Troy A.

AU - Guzman, Mike

AU - Sando, Ian C.

AU - Sharma, Rahul

AU - Meldrum, Daniel R.

PY - 2009/4

Y1 - 2009/4

N2 - Background: Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen is implicated in the cardioprotection found in females. It remains unknown whether 17β-estradiol (E2) affects MSC paracrine function and whether E2-treated MSCs may better protect injured cardiac tissue. We hypothesize that E2-exposed MSCs infused into hearts prior to ischemia may demonstrate increased vascular endothelial growth factor (VEGF) production and greater protection of myocardial function compared to untreated MSCs. Materials and methods: Untreated and E2-treated MSCs were isolated, cultured, and plated and supernatants were harvested for VEGF assay (enzyme-linked immunosorbent assay). Adult male Sprague-Dawley rat hearts (n = 13) were isolated and perfused via Langendorff model and subjected to 15 min equilibration, 25 min warm global ischemia, and 40 min reperfusion. Hearts were randomly assigned to perfusate vehicle, untreated male MSC, or E2-treated male MSC. Transcoronary delivery of 1 million MSCs was performed immediately prior to ischemia in experimental hearts. Results: E2-treated MSCs provoked significantly more VEGF production than untreated MSCs (933.2 ± 64.9 versus 595.8 ± 10.7 pg/mL). Postischemic recovery of left ventricular developed pressure was significantly greater in hearts infused with E2-treated MSCs (66.9 ± 3.3%) than untreated MSCs (48.7 ± 3.7%) and vehicle (28.9 ± 4.6%) at end reperfusion. There was also greater recovery of the end diastolic pressure with E2-treated MSCs than untreated MSCs and vehicle. Conclusions: Preischemic infusion of MSCs protects myocardial function and viability. E2-treated MSCs may enhance this paracrine protection, which suggests that ex vivo modification of MSCs may improve therapeutic outcome.

AB - Background: Stem cell therapy is a promising treatment modality for injured cardiac tissue. A novel mechanism for this cardioprotection may include paracrine actions. Our lab has recently shown that gender differences exist in mesenchymal stem cell (MSC) paracrine function. Estrogen is implicated in the cardioprotection found in females. It remains unknown whether 17β-estradiol (E2) affects MSC paracrine function and whether E2-treated MSCs may better protect injured cardiac tissue. We hypothesize that E2-exposed MSCs infused into hearts prior to ischemia may demonstrate increased vascular endothelial growth factor (VEGF) production and greater protection of myocardial function compared to untreated MSCs. Materials and methods: Untreated and E2-treated MSCs were isolated, cultured, and plated and supernatants were harvested for VEGF assay (enzyme-linked immunosorbent assay). Adult male Sprague-Dawley rat hearts (n = 13) were isolated and perfused via Langendorff model and subjected to 15 min equilibration, 25 min warm global ischemia, and 40 min reperfusion. Hearts were randomly assigned to perfusate vehicle, untreated male MSC, or E2-treated male MSC. Transcoronary delivery of 1 million MSCs was performed immediately prior to ischemia in experimental hearts. Results: E2-treated MSCs provoked significantly more VEGF production than untreated MSCs (933.2 ± 64.9 versus 595.8 ± 10.7 pg/mL). Postischemic recovery of left ventricular developed pressure was significantly greater in hearts infused with E2-treated MSCs (66.9 ± 3.3%) than untreated MSCs (48.7 ± 3.7%) and vehicle (28.9 ± 4.6%) at end reperfusion. There was also greater recovery of the end diastolic pressure with E2-treated MSCs than untreated MSCs and vehicle. Conclusions: Preischemic infusion of MSCs protects myocardial function and viability. E2-treated MSCs may enhance this paracrine protection, which suggests that ex vivo modification of MSCs may improve therapeutic outcome.

KW - cardioprotection

KW - estrogen

KW - paracrine

KW - sex hormones

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=61849084197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849084197&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2008.02.006

DO - 10.1016/j.jss.2008.02.006

M3 - Article

C2 - 18511080

AN - SCOPUS:61849084197

VL - 152

SP - 319

EP - 324

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -